The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Clinical Implications of Sarcopenic Obesity in Cancer
Abstract
Sarcopenia has been associated with several negative clinical outcomes in cancer. However, the consequences of sarcopenic obesity, a condition of combined sarcopenia and obesity burden, have been less extensively investigated. The aim of this paper was to review the current evidence on the prevalence and clinical implications of sarcopenic obesity in cancer. A total of 14 studies linking sarcopenic obesity to a clinical outcome in cancer were included. There is considerable inconsistency in methods used to evaluate body composition as well as in the criteria used to define sarcopenic obesity, which limits comparison among studies. Therefore, the prevalence of sarcopenic obesity varied substantially: between 1 and 29 % in studies including individuals from all body mass index categories and between 15 and 36 % for those including obese individuals only. Negative clinical outcomes reported to be associated with sarcopenic obesity included higher risk of dose-limiting toxicity, surgical complications, physical disability, and shorter survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, adverse clinical cancer outcomes reported to be relevant to SO, especially with respect to dose-limiting toxicity, surgical complications, physical disability, and shorter survival (59–61).”
From Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments (2020) · cites this paper as [60]
Citations
Cites
(2000) · PubMed · Cited by 13,173
The Disease Burden Associated With Overweight and Obesity
Must, A. (1999) · JAMA · doi:10.1001/jama.282.16.1523 · Cited by 4,827
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Adipocytokines: mediators linking adipose tissue, inflammation and immunity
Tilg, H., & Moschen, A. R. (2006) · Nature reviews. Immunology · doi:10.1038/nri1937 · Cited by 3,272
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Self-citationMartin, L., Birdsell, L., Macdonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., Murphy, R. A., Ghosh, S., Sawyer, M. B., & Baracos, V. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2722 · Cited by 2,761
Bruera, E. D., Kuehn, N., Miller, M. J., Selmser, P., & Macmillan, K. (1991) · Journal of Palliative Care · doi:10.1177/082585979100700202 · Cited by 2,686
Mourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224
Self-citationShen, W., Punyanitya, M., Wang, Z., Gallagher, D., St.-Onge, M.-P., Albu, J., Heymsfield, S. B., & Heshka, S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00744.2004 · Cited by 1,692
Research works printed but not linked: 1
- Canadian Cancer Society. 2014 edition of Canadian cancer statistics. 2014. http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=on .
Cited by
Sorted by citations
Items 101–162 of 162
Jobber, C., Wilkinson, S. A., Hughes, E., Nave, F., & van der Meij, B. S. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06375-7 · Cited by 8
“elderly [38]; liver failure [53–55]; oncology [56, 57]; renal disease [58]; and respiratory disease [32]) none have applied this across a hospital dietetics”
BackgroundHorino, T., Tokunaga, R., Miyamoto, Y., Hiyoshi, Y., Akiyama, T., Daitoku, N., Sakamoto, Y., Yoshida, N., & Baba, H. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02293-2 · Cited by 7
Sarcopenia: Loss of mighty armor against frailty and aging
Sasako, T., & Ueki, K. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14067 · Cited by 7
“Indeed, subcutaneously transplanted melanoma cells grow faster in the sarcopenia model mice 5 , consistent with the poor prognosis of cancer in humans with sarcopenic obesity 9,10 .”
Palmas-Candia, F. X., Ricart, M., Lluch, A., Mucarzel, F., Cartiel, R., Zabalegui, A., Barrera, E., Rosón, N., Rodríguez-Martínez, A., Espín, E., et al. (2025) · Nutrients · doi:10.3390/nu17142264 · Cited by 6
Clinical implication of preoperative psoas muscle area in endometrial cancer patients
Bilir, F., Özgül, E., Elaziz, B., & Arıöz, D. T. (2021) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20210364 · Cited by 6
Edwards, A., Hughes, B. G. M., Brown, T. E., & Bauer, J. (2022) · Advances in Nutrition · doi:10.1093/advances/nmac076 · Cited by 7
“Recent evidence also suggests that patients with sarcopenic obesity display lower rates of febrile neutropenia, implying potential “under-dosing" of patients (60, 61).”
BackgroundUchida, S., Sohda, M., Tateno, K., Watanabe, T., Shibasaki, Y., Nakazawa, N., Kuriyama, K., Sano, A., Yokobori, T., Sakai, M., et al. (2023) · Esophagus · doi:10.1007/s10388-023-01034-8 · Cited by 6
“Sarcopenic obesity is associated with several specific adverse clinical outcomes, including a high risk of postoperative complications, extended hospital stays, and poor survival owing to the combined burden of sarcopenia and obesity [25].”
Chemotherapy dosing and toxicity in a patient with muscular dystrophy
Lomma, C., & Ransom, D. T. (2018) · Cancer Reports · doi:10.1002/cnr2.1106 · Cited by 6
“However, more recently sarcopenic obesity (obesity in conjunction with low skeletal muscle mass) has been recognised as a predictor of both toxicity to chemotherapy and poor prognosis.(11,12) One hypothesis for the increased toxicity in sarcopenic obesity is the combination of higher doses of chemotherapy with reduced…”
BackgroundSadok, N., Hartmans, M. E., de Bock, G. H., Klaase, J. M., Werker, P. M. N., Viddeleer, A. R., & Jansen, L. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09381 · Cited by 6
“Sarcopenic obesity was defined as BMI>25 & SMI <39 based on the literature [11, 12].”
BackgroundMethodCarnevale, S., Vitale, A., Razzi, M., Onori, C., Cornacchia, G., Grispo, O., Corsinovi, E., Rossl, L., Spinetti, E., Tosi, M., et al. (2024) · Dietetics · doi:10.3390/dietetics3040039 · Cited by 5
Herzberg, J., Strate, T. G., Passlack, L., Guraya, S. Y., & Honarpisheh, H. (2024) · Cancers · doi:10.3390/cancers16244217 · Cited by 5
He, J., Huang, Y., Huang, N., & Jiang, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1363843 · Cited by 5
Schenk, J. M., Gulati, R., Beatty, S. J., Plymate, S. R., Lin, D. W., Dash, A., Porter, M. P., VanDoren, M., Wright, J. L., & Neuhouser, M. L. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf113 · Cited by 4
Sarcopenia en pacientes oncológicos en tratamiento Quimioterápico
Santos, K. T. D. O., Gomes, F. M. A., da Silva, S. M. E., da Silva, A. R. A., & Pinho, C. P. S. (2019) · Revista chilena de nutrición · doi:10.4067/s0717-75182019000400375 · Cited by 4
Ohashi, N., Koike, K., Sakai, K., Nishiyama, K., Sasaki, T., Ogi, K., Dehari, H., Kobayashi, N., & Miyazaki, A. (2022) · Oral Radiology · doi:10.1007/s11282-022-00653-8 · Cited by 4
“Malnutrition and body composition are increasingly assessed in such patients [1, 2]; according to some reports, sarcopenia is a predictor of poor outcomes in patients with head and neck cancers [3–5].”
BackgroundA scientometric analysis of sarcopenic obesity: Future trends and new perspectives
Tutan, D., & Uzeli, Ü. Ş. (2023) · Medicine · doi:10.1097/md.0000000000034244 · Cited by 4
“[4–6] It is estimated that up to 30% of older adults may be affected by this condition.[7] Its prevalence varies by gender, race, and ethnicity with higher incidence rates in Asian males and females.”
BackgroundMachado, V. M. Q., Justa, R. M. D. E., da Costa, S. L., Barbosa, M. C., Damasceno, N. R. T., & Verde, S. M. M. L. (2021) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2021.06.008 · Cited by 4
Lellouche, L., Barat, M., Pellat, A., Leroux, J., Corre, F., Hallit, R., Assaf, A., Brézault, C., Dhooge, M., Soyer, P. A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062211 · Cited by 3
Landscape and research trends of sarcopenic obesity research: A bibliometric analysis
Tang, H., Lian, R., Li, R., Jiang, J., & Yang, M. J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24696 · Cited by 3
“It was estimated that up to 30.0 % of older adults may be affected by this condition [5], increasing risk of adverse health-related outcomes.”
BackgroundInfluentialXing, J., Wang, Y., Cao, M., Shan, F., Li, S., Jia, Y., Xue, K., Miao, R., Li, Z., Yan, C., et al. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.109752 · Cited by 3
Godziuk, K., Prado, C. M. M., Woodhouse, L. J., & Forhan, M. A. (2021) · Obesity · doi:10.1002/oby.23074 · Cited by 3
“This condition has been identified in several clinical populations (including patients with cancer (3), heart failure (4), and orthopedic conditions (5,6)), with indications that it can negatively impact treatment outcomes.”
BackgroundSelf-citationYu, J. H., Lee, H. T., Jang, S. K., Lee, A. Y., & Seo, J. (2025) · Clinical Endoscopy · doi:10.5946/ce.2024.209 · Cited by 3
Zhang, J., Wang, J., Zhou, J., Fang, Q., Zhang, N., & Yuan, C. (2019) · Journal of Advanced Nursing · doi:10.1111/jan.14040 · Cited by 3
Hinojo, C., Cantos, B., Antolín, S., Arqueros, C., Díaz-Redondo, T., González, I., Llabrés, E., Ramírez, J. A., Barral, M., Escudero, M., et al. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.12.016 · Cited by 2
Bouleftour, W., Aurane, R., Tinquaut, F., Rivoirard, R., & Forges, F. (2025) · Scientific Reports · doi:10.1038/s41598-025-14279-3 · Cited by 2
Jiang, Y., Jiang, W., Wang, Q., Wei, T., & Chan, L. (2025) · Bioengineering · doi:10.3390/bioengineering12090921 · Cited by 2
“Existing research shows that cancer patients with SO are at special risk for adverse outcomes, leading to a reduction in quality of life, complications after surgical resection, increased risk of dose-limiting toxicity during chemotherapy, and increased mortality [9].”
COMPOSIÇÃO CORPORAL E ESTADO MENOPAUSAL EM MULHERES COM CÂNCER DE MAMA: UMA REVISÃO DA LITERATURA
Poltronieri, T. S., & Liberali, R. (2018) · Revista de Atenção à Saúde · doi:10.13037/ras.vol16n57.5347 · Cited by 2
The Modulation of Adipokines, Adipomyokines, and Sleep Disorders on Carcinogenesis
Brzecka, A., Martynowicz, H., Daroszewski, C., MAJCHRZAK, M. W., Ejma, M., Misiuk‐Hojło, M., Somasundaram, S. G., Kirkland, C. E., & Kosacka, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072655 · Cited by 1
“A meta-analysis of 14 studies of cancer patients revealed negative clinical outcomes associated with sarcopenic obesity, such as increased drug toxicity, more frequent surgical complications, and shortened survival [40].”
BackgroundResultSun, J. X., Hwang, J., Fredette, J. D., Papai, E., Miller, L., Krempa, J., Rives, H., & Reddy, S. S. (2025) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2025.102157 · Cited by 1
MEDINA, A. A., Bajawi, M., Perez, E. L., Fernández, S. G., Curtis, D. A. L., Pascual, L. E., Subiela, J. D., Soto, J., Góngora, C. N., Tello, F. G., et al. (2025) · Cancers · doi:10.3390/cancers17162669 · Cited by 1
“Nevertheless, the impact of SO, a condition involving a combination of sarcopenia and obesity burden, has been investigated less frequently, particularly in the field of bladder cancer [4].”
InfluentialPerspective: Radiotherapy and Body Composition: Unmet Needs in Low- and Middle-Income Countries
Murphy‐Alford, A. J., Grossberg, A. J., Baracos, V. E., Barbar, M., Bauer, J. D., Bennett, J. P., Fidarova, E. F., Fuller, C. D., Löser, A., Moreno, A. C., et al. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100563 · Cited by 1
“The prevalence of sarcopenic obesity in cancer patients has been reported from 1% to 29% [57], with a meta-analysis showing a pooled prevalence of 20% [58], though this was not only in patients receiving RT.”
Recent advances in the research of sarcopenia in colorectal cancer
Wang, Y., Wang, Y., & Liu, M. R. (2025) · Holistic Integrative Oncology · doi:10.1007/s44178-025-00210-3 · Cited by 1
Chun, S., Lee, H. S., Jung, J.-H., Kim, S. H., Cho, I. Y., Han, K., & Shin, D. W. (2026) · Breast Cancer Research and Treatment · doi:10.1007/s10549-026-07899-4 · Cited by 1
“Both sarcopenic obesity and cancer share key pathogenetic mechanisms, including systemic inflammation, oxidative stress, and insulin resistance [35].”
Nutritional Profile of Oncology Patients from an Outpatient Nutritional Service in Brazil
Pigioni, V. B., Manca, C. S., Chiarello, P. G., & Sicchieri, J. M. F. (2020) · journal of nutritional oncology · doi:10.34175/jno202004003 · Cited by 1
“However, the patients with advanced disease are often unable to maintain a routine with physical exercise, so focusing on the nutritional approach may provide a greater possibility of successful intervention without adverse effects [14].”
BackgroundInfluentialLee, H., Reilly, M., Bruner, D. W., Bai, J., Hu, Y., & Yeager, K. A. (2022) · Research in Nursing & Health · doi:10.1002/nur.22272 · Cited by 1
Jobber, C., Wilkinson, S. A., Hughes, E., Nave, F., & van der Meij, B. S. (2020) · Research Square · doi:10.21203/rs.3.rs-113964/v1 · Cited by 1
Physical Inactivity, Adverse Body Composition, and Cardiac Function in Breast Cancer Survivors
Kirkham, A. A., Power, C., & Pituskin, E. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.03.001 · Cited by 1
Lewandowska, A., Woźniak, A. E., Budziszewska, B. K., Góra‐Tybor, J., Jamroziak, K., Lech‐Marańda, E., & Warzocha, K. (2017) · Hematologia · doi:10.5603/hem.2017.0014
Sarcopenia in Oncology or Gerontology: What Is the Difference?
Shachar, S. S., & Shafran, N. (2017) · Current Geriatrics Reports · doi:10.1007/s13670-017-0220-2
Colorectal Cancer Survivorship: Steps towards integrative oncology and patient-centered cancer care
Derksen, H. W. G. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/128
Sarcopenia in head and neck cancer
Chargi, N. (2021) · doi:10.33540/804
Lawson, C. (2021) · eScholarship@McGill (McGill) · doi:10.82308/49325
Laryngectomy: complications & survival
Pézier, T. F. (2021) · doi:10.33540/872
Skeletal muscle mass in head and neck cancer patients
Bril, S. I. (2021) · doi:10.33540/1001
Siddaiah‐Subramanya, M., Sinha, Y., Kamarajah, S. K., Ghoneim, A. H., Halle-Smith, J. M., & Tan, B. H. L. (2021) · Foregut The Journal of the American Foregut Society · doi:10.1177/26345161211063448
Frailty in the Perioperative Setting for Cancer Patients
Lin, H., Reid, N., & Hubbard, R. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-69584-8.00035-9
de Souza, M. T. P. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2022.tde-20042023-111514
Jiang, Y., Yang, C., Zhang, J., Luo, P., Jiang, W., & Wei, T. (2023) · Research Square · doi:10.21203/rs.3.rs-3099213/v1
Mama, N., Cucchiaro, B., & Slee, A. (2023) · Clinical Nutrition Open Science · doi:10.1016/j.nutos.2023.08.008
“In addition, poorer clinical outcomes have been reported during chemotherapy in participants with a higher percentage body fat [37].”
Janowska, N., Łyczek, A., Komorniak, N., Jakubiak, N., Kaźmierczak-Siedlecka, K., & Stachowska, E. (2024) · Nowotwory Journal of Oncology · doi:10.5603/njo.100530
Prognostic significance of MRI-derived sarcopenia in patients with endometrial cancer
Aybal, T., Keleş, E., Kahyaoğlu, B., & DEMİRDEN, A. (2025) · Abdominal Radiology · doi:10.1007/s00261-025-05147-9
Jobber, C., Wilkinson, S. A., Hughes, E., Nave, F., & van der Meij, B. S. (2021) · Figshare · doi:10.6084/m9.figshare.14700455
Jennerich, A. L., Downey, L., Goss, C. H., Kapnadak, S. G., Pryor, J. B., & Ramos, K. J. (2023) · Figshare · doi:10.6084/m9.figshare.22621988
Effect of Preoperative Sarcopenic Obesity on Outcomes in Patients with Gastric Cancer After Surgery
HASHIMOTO, I., KOMORI, K., Akimoto, N., Nakayama, Y., Nagasawa, S., Maezawa, Y., KANEMATSU, K., Yamada, T., Yukawa, N., Saito, A., et al. (2026) · Cancers · doi:10.3390/cancers18020191
“Previous studies have shown that SO contributes to poor short-and long-term outcomes in various cancers [11–13].”
Xu, H., Hu, Y., Yu, J., Han, X., Qi, C., & Jiang, H. (2026) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2026.111786
Rouse, M., Kokelaar, R., Lee, I., & Yeung, J. M. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.05.027
Fanaki, M., Haidopoulos, D. A., Vlachos, D., Lygizos, V., Varthaliti, A., Pergialiotis, V., Daskalakis, G., & Thomakos, N. (2026) · Nutrients · doi:10.3390/nu18121905
“Its prevalence rates vary depending on population and diagnostic criteria, but may affect up to 15–36% of obese cancer patients in critical care [33], and has been increasingly recognized as a major contributor to adverse clinical outcomes in cancer patients, including those with gynecologic…”
Low muscle mass predicts poor response to neoadjuvant chemotherapy in advanced ovarian cancer
Esmer, D. D., Hafızoğlu, E., Bardakçı, M., Özkan, E., Sekmek, S., Bayram, D., Karahan, İ., Algın, E., & Bal, Ö. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-025-01960-4
“Previous reviews have also highlighted the poor clinical outcomes associated with sarcopenic obesity across malignancies [17].”
Bouh, A., Moufid, A., Ghoulam, N. E., Daoudi, D., LKHOYAALI, S., Hafi, Z. E., Benaich, S., Aguenaou, H., Mehdad, S., & Boutayeb, S. (2026) · Mediterranean Journal of Nutrition and Metabolism · doi:10.1177/1973798x261465437
“57 In this study, patients who were not malnourished had signi fi cantly lower odds of losing weight, but a higher likelihood of having low muscle mass.”
Lima, M. D. S., Bitencourt, A. G. V., & Miola, T. M. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-11086-y
“[7, 18, 19].”
Low muscle mass, obesity, and cause-specific mortality in cancer patients: a nationwide cohort study
Lee, D., Kim, B., Jung, K.-W., Nam, G. E., Rhee, S. Y., Kim, S. P., Chun, S., Cho, I. Y., Han, K., & Shin, D. W. (2026) · Cancer Causes & Control · doi:10.1007/s10552-026-02244-y
Metadata
- Authors
- Carneiro, I. P., Mazurak, V. C., & Prado, C. M.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Prado, Carla M.
- Venue
- Current Oncology Reports
- Published
- 2016-08-19
- Volume
- 18
- Issue
- 10
- Pages
- 62-62
- ISSN
- 1523-3790 (ISSN-L)
- 1534-6269
- OpenAlex
- W2518082324
- Cited by
- 162
- References
- 77
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 15 · 2023: 19 · 2022: 15 · 2021: 23 · 2020: 22 · 2019: 19 · 2018: 17 · 2017: 9 · 2016: 1
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Oncology Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
- Health Sciences › Medicine › Geriatrics and Gerontology › Frailty in Older Adults
- Keywords
- sarcopenic obesity, sarcopenia, obesity, cancer, body composition, prevalence, dose-limiting toxicity, surgical complications, physical disability, survival, clinical outcomes
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Body Composition, Dose-Response Relationship, Drug, Humans, Neoplasms, Obesity, Prevalence, Survival Analysis, Treatment Outcome, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
